May 14, 2020
binx health Announces Publication of Pivotal Study in JAMA Network Open
Apr 30, 2020
binx health Announces Second FDA 510(k) Clearance Of Its Molecular Point-Of-Care Infectious Disease Platform
Jan 13, 2020
Given market demand, binx health announces launch of pre-order program for its first-of-kind rapid, molecular point-of-care platform
Dec 18, 2019
U.S. FDA Acknowledges Receipt of Evofem Biosciences' New Drug Application Resubmission for Amphora® for the Prevention of Pregnancy
Dec 03, 2019
PDL BioPharma Congratulates Evofem Biosciences on Achieving Major Regulatory and Clinical Milestones with its Lead Product Candidate Amphora®
Nov 13, 2019
Evofem Biosciences to Participate in Upcoming Investor Conferences
Sep 25, 2019
Evofem Biosciences to Present at Cantor Global Healthcare Conference on October 4, 2019
Aug 26, 2019
Evofem Biosciences Completes Phase 2b 'AMPREVENCE' Trial of Amphora for Prevention of Chlamydia and Gonorrhea in Women
Aug 22, 2019
Evofem Biosciences to Present at Upcoming Healthcare Conferences
Aug 12, 2019
binx health Receives FDA 510(k) Clearance For Rapid Point Of Care Platform For Women's Health
Jun 18, 2019
UMN Medical School Report Shows Sexually Transmitted Infections at All-Time High Among MN Youth
May 29, 2019
Cepheid Receives FDA Clearance for Extragenital Claims for Xpert® CT/NG Test
May 23, 2019
FDA clears first diagnostic tests for extragenital testing for chlamydia and gonorrhea
May 01, 2019
binx health Receives CE Mark For Rapid Chlamydia And Gonorrhea Test For Mass Markets
Apr 23, 2019
Evofem Biosciences Announces Last Patient Enrolled for AMPREVENCE, the Phase 2b Sexually Transmitted Infections Trial of Amphora
Jan 03, 2019
Evofem Biosciences Provides Corporate Update and Announces Upcoming Milestones
Nov 08, 2018
Evofem Biosciences Completes Phase 3 Clinical Trial of Amphora for Prevention of Pregnancy
Nov 07, 2018
Evofem Biosciences Reports Third Quarter 2018 Financial Results and Provides Corporate Update
Oct 09, 2018
Data on Patient Acceptability and Genitourinary Effects of Evofem Biosciences' Lead Product Candidate, Amphora, and its Role as a Multipurpose Vaginal pH Regulator Presented at 2018 American Society of Reproductive Medicine Annual Congress
Oct 03, 2018
Evofem Biosciences to Present Data on Methodology and Current Status of Two Ongoing Clinical Studies of Amphora at the 2018 International Federation of Gynecology and Obstetrics (FIGO) World Congress